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Abstract
Introduction: Timely diagnosis of pneumonia in intubated critically ill patients is rather challenging. Pentraxin 3
(PTX3) is an acute-phase mediator produced by various cell types in the lungs. Animal studies have shown that,
during pneumonia, PTX3 participates in fine-tuning of inflammation (for example, microbial clearance and
recruitment of neutrophils). We previously described an association between alveolar PTX3 and lung infection in a
small group of intubated patients. The aim of the present study was to determine a threshold level of alveolar PTX3
with elevated sensitivity and specificity for microbiologically confirmed pneumonia.
Methods: We recruited 82 intubated patients from two intensive care units (San Gerardo Hospital, Monza, Italy, and
Massachusetts General Hospital, Boston, MA, USA) undergoing bronchoalveolar lavage (BAL) as per clinical decision.
We collected BAL fluid and plasma samples, together with relevant clinical and microbiological data. We assayed
PTX3 and soluble triggering receptor expressed on myeloid cells 1 (sTREM-1) in BAL fluid and PTX3, sTREM-1,
C-reactive protein (CRP) and procalcitonin (PCT) in plasma. Two blinded independent physicians reviewed patient
data to confirm pneumonia. We determined the PTX3 threshold in BAL fluid for pneumonia and compared it to
other biomarkers.
Results: Microbiologically confirmed pneumonia of bacterial (n =12), viral (n =4) or fungal (n =8) etiology was
diagnosed in 24 patients (29%). PTX3 levels in BAL fluid predicted pneumonia with an area under the receiving
operator curve of 0.815 (95% CI =0.710 to 0.921, P <0.0001), whereas none of the other biomarkers were effective.
In particular, PTX3 levels ≥1 ng/ml in BAL fluid predicted pneumonia in univariate analysis (β =2.784, SE =0.792,
P <0.001) with elevated sensitivity (92%), specificity (60%) and negative predictive value (95%). Net reclassification
index PTX3 values ≥1 ng/ml in BAL fluid for pneumonia indicated gain in sensitivity and/or specificity vs. all other
mediators. These results did not change when we limited our analyses only to confirmed cases of bacterial
pneumonia. Moreover, when we considered only the 70 patients who fulfilled the clinical criteria for the diagnosis
of pneumonia at BAL fluid sampling, the diagnostic accuracy of PTX levels was confirmed in univariate and ROC
curve analysis.
Conclusions: In this hypothesis-generating convenience sample, a PTX3 level ≥1 ng/ml in BAL fluid was
discriminative of microbiologically confirmed pneumonia in mechanically ventilated patients.
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Timely and accurate diagnosis of pneumonia is a challen-
ging task for intensive care unit (ICU) physicians [1]. Ac-
cording to the Centers for Disease Control and Prevention
guidelines, the clinical diagnosis is made on the basis of
the presence of fever, leukocytosis, purulent lung secre-
tions and new infiltrates seen on chest X-rays [2]. Micro-
biological culture of bronchoalveolar lavage (BAL) fluid
represents an accepted standard to confirm (or exclude) a
clinical diagnosis of pneumonia in intubated ICU patients
[3], but it generally takes 48 hours to obtain results [4].
Meanwhile, physicians usually prescribe either broad-
spectrum antibiotics [5] or probability-based, narrow-
spectrum antibiotics [6]. In fact, both approaches yield
many false-positive pneumonia diagnoses, resulting in
these patients being given unnecessary antibiotics until
culture results become available [7]. Thus, extensive re-
search efforts have been spent in recent years to accelerate
rapid and accurate diagnosis of pneumonia in ICU patients
[8-11]. For example, the Clinical Pulmonary Infection Score
(CPIS) has proved helpful in diagnosing ventilator-
associated pneumonia (VAP) [9]. Measuring circulating
procalcitonin (PCT) levels has been shown to be effective
in guiding antibiotic therapy in critically ill patients with
suspected bacterial infection without adverse events [10]. In
another study, researchers proposed soluble triggering re-
ceptor expressed on myeloid cells 1 (sTREM-1) in BAL
fluid as an early biomarker for the diagnosis of pneumonia
in intubated patients [8]. However, CPIS has been validated
only for making a VAP diagnosis, and PCT and sTREM-1
results have been challenged [11-14]. To our knowledge, an
accurate and reliable early marker for pneumonia in intu-
bated ICU patients is still lacking.
Pentraxin 3 (PTX3) is an acute-phase inflammatory me-
diator produced at the site of infection that can be assayed
in a few hours [15]. In the lungs, epithelial cells, endothe-
lial cells and leukocytes can produce PTX3 if appropriately
stimulated [15-17]. During experimental pneumonia,
PTX3 has been shown to recognize different infectious
agents (that is, bacteria, viruses and fungi) and to enhance
their clearance, primarily by regulation of neutrophil
recruitment [18-20]. In humans, plasma PTX3 levels cor-
relate with clinical severity in many infectious diseases
[21-24]. Circulating PTX3 is elevated in the most severe
forms of VAP and community-acquired pneumonia
(CAP) [25,26], and pleural fluid PTX3 measurement im-
proves discrimination of parapneumonic effusions [27].
We previously described an association between detect-
able alveolar PTX3 levels and lung infections of any eti-
ology in a small group of intubated patients with acute
respiratory distress syndrome (ARDS) [28].
Given the sound pathophysiological background and
the experimental data in animal models and patients, we
conducted the present two-center international study to
identify the threshold PTX3 level in BAL fluid for accur-
ate diagnosis of microbiologically confirmed pneumonia
and compare the diagnostic accuracy of alveolar PTX3
levels with those of other biomarkers.
Methods
Study population
We performed a prospective, threshold-finding observa-
tional study with patients admitted to two university-
affiliated ICUs (San Gerardo Hospital, Monza, Italy, and
Massachusetts General Hospital, Boston, MA, USA). The
inclusion criteria were age ≥18 years, intubation and mech-
anical ventilation and BAL fluid obtained as per clinical de-
cision. The exclusion criteria were insufficient quantity of
recovered BAL fluid, BAL performed in a patient previously
enrolled in the same study, organizational reasons (for ex-
ample, temporary unavailability of the research team) and
refusal to give consent. The ethics committee of the San
Gerardo Hospital and the Partners Human Research Com-
mittee of the Massachusetts General Hospital approved the
research protocol. Informed consent was obtained either
from the patients or, when deemed incompetent to provide
consent, from their next of kin.
Bronchoalveolar lavage fluid collection and analysis
BAL fluid was obtained using a standard technique [28].
Briefly, a fiberscope was aseptically introduced through the
endotracheal tube to the most peripheral bronchus of the
radiographically positive lobe (that is, where new pulmon-
ary infiltrates seemed evident). Next, fixed aliquots (n =6,
20 ml each) of 0.9% sterile saline solution were instilled into
the aforementioned lobe, and each aliquot was gently aspi-
rated. Each BAL procedure took 10 to 20 minutes to per-
form. The first recovered BAL fluid portion was discarded.
The remainder was mixed and sent in part to the micro-
biology department (for bacterial quantitative cultures as
appropriate; for viruses (Aspergillus fumigatus, Candida
spp and Pneumocystis carinii), cultures were obtained only
when clinically suspected (that is, in immunocompromised
patients)) and in part to the cytology department for semi-
quantitative leukocyte counts (ranging from no leuko-
cytes (−) to few (+) or many (++ or +++)). The
remaining BAL fluid was centrifuged, and the super-
natant was stored at −80°C, along with one plasma sam-
ple. Within 1 month after fluid and plasma collection,
biological samples were transferred in dry ice to the De-
partment of Inflammation and Immunology, Humanitas
Clinical and Research Center, Rozzano (MI), Italy.
Upon arrival of the fluid samples, biomarkers were
assayed in duplicate using the following procedures. (1) In
one experiment, plasma and alveolar PTX3 was assayed
with a specific enzyme-linked immunosorbent assay (ELISA)
kit developed in-house (intra- and interassay coefficients of
variation <10%, sensitivity of 0.1 ng/ml, assay dynamic range
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ples were diluted at a 1:2 to 1:18 ratio and plasma speci-
mens at a 1:5 to 1:90 ratio. This assay does not cross-react
with C-reactive protein (CRP) or serum amyloid A protein.
T h et i m er e q u i r e dt op e r f o r mas i n g l em e a s u r e m e n tw a s
about 6 to 7 hours. The cost to perform one measurement
was €5 per patient [28]. (2) Plasma and BAL fluid sTREM-
1 levels were measured using a commercially available
sandwich ELISA kit (Sigma-Aldrich, St Louis, MO, USA)
following the manufacturer instructions (detection limit
8 pg/ml). We also performed in-house validation mea-
surements (see Additional file 1). (3) We measured plasma
CRP levels by turbidimetric immunoassay (Roche/Hitachi
Modular PRE-ANALYTICS system, P module; Roche
Diagnostics, Milan, Italy). (4) Plasma PCT levels were
measured using commercially available kits (Elecsys
BRAHMS PCT Assay; Roche Diagnostics, Mannheim,
Germany), with a detection limit of 0.02 ng/ml. On the
same day as BAL was performed, we recorded patients’
comorbidities and several parameters of disease severity.
Diagnosis of pneumonia
Two experienced intensivists blinded to biomarker levels
and to the initial clinical diagnoses independently reviewed
BAL cultures and patients’ medical records to classify each
case as CAP (defined as clinical suspicion of pneumonia
arising <48 hours after hospital admission), healthcare-
associated pneumonia (HCAP, defined as clinical suspicion
of pneumonia arising <48 hours after hospital admission in
a patient recently hospitalized and/or living in a nursing
home or long-term care facility and/or who received paren-
teral antimicrobial therapy within 30 days before diagnosis
of pneumonia), hospital-acquired pneumonia (HAP, defined
as clinical suspicion arising ≥48 hours after hospital admis-
sion and intubation initiated <48 hours after hospital ad-
mission), VAP (clinical suspicion arising ≥48 hours after
hospital admission and intubation performed ≥48 hours
after hospital admission) or no pneumonia [2,6,8]. The
pneumonia diagnosis was based upon the following stand-
ard criteria [29]:
1. New and persistent radiographic infiltrates
associated with at least two of the following:
a. Internal body temperature >38°C,
b. White blood cells count >12,000 or <4,000 cells/
mm
3 and/or
c. Purulent tracheobronchial secretions; as well as with:
2. A positive BAL culture (that is, noncontaminant
bacteria or fungi identified in 10
4 or more colony-
forming units per milliliter and/or significant non-
contaminant viral load).
Pneumonia cases of fungal and viral etiology were care-
fully reviewed and then confirmed if risk factors were
present (for example, immunosuppression), airway
colonization was excluded (for example, presence of
systemic infection signs, contemporary presence of
other biofluids infected by the same pathogen, exclusion
of other infection sites) and specific antifungal or anti-
viral therapy was started.
Pneumonia was considered absent when clinical signs
of pneumonia were not present at the time of BAL fluid
sampling and/or when an alternative cause for pulmon-
ary infiltrate was established and there was no significant
growth in BAL cultures and/or colonization, together
with absence or full recovery from clinical signs of sepsis
without any or new antibiotic therapy.
Immunostaining to measure cell fractions positive for
intracellular PTX3
The cell pellets of 20 BAL fluid aliquots (24%) from 20
consecutive patients (all enrolled in Monza, Italy) were
resuspended, spun and stained to measure the fraction
of cells in BAL fluid positive for intracellular PTX3, as
previously described [30].
Statistical analysis
Statistical analysis was performed using SAS 9.2 software
(SAS Institute, Cary, NC, USA). A P-value <0.05 was con-
sidered statistically significant. The percentage agreement
and Cohen’s κ were calculated to compare the performance
of the two independent intensivists’ assessments of the
pneumonia diagnoses [31]. Normally distributed variables
(Shapiro-Wilk test) are reported as mean ±standard devi-
ation, and non-normal variables as median and interquartile
range (IQR). Comparisons of quantitative variables were car-
ried out using Student’s t-test or the Mann–Whitney U test
as appropriate. For comparison of categorical variables, a χ
2
test or Fisher’s exact test (in cases of small cell sizes,
expected values <5) was performed. The correlation coeffi-
cient between biomarkers was analyzed using Spearman’s
ρ coefficient.
The discriminatory ability of each biomarker was mea-
sured as the area under the receiving operating character-
istic curve (AUC
ROC) with pneumonia as the outcome of
interest. AUC
ROC values with 95% CIs and P-values for
differences from chance are reported. Sensitivity, specifi-
city, positive predictive value (PPV), negative predictive
value (NPV) and Youden index [32] values were com-
puted to evaluate the PTX3 thresholds in BAL fluid and
plasma with highest discriminatory ability for pneumonia.
Univariate logistic regression was used to determine pre-
dictors of pneumonia. β-values (that is, log odds ratio),
standard errors (SEs) and P-values for differences from 0
(the Wald statistic) are reported. The net reclassification
index (NRI) was used to compare the performance of the
identified cutoff PTX3 levels in BAL fluid vs. other bio-
markers and CPIS; that is, we used the cutoff identified by
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cepted cutoffs for all other mediators and CPIS. More de-
tails on the methods used in this study can be found in
Additional file 1.
Results
Study population
We enrolled a convenience sample of 82 patients, in-
cluding 64 in Monza between April 2009 and July 2011
and 18 in Boston between January and July 2011.
Figure 1 presents a flow diagram for the study popula-
tion. The reasons reported by the attending physicians
for performing BAL in these patients were suspected
lung infection (n =66; 80%), suspected aspiration pneu-
monia (n =3; 4%), suspected malignancies (n =4; 5%),
suspected autoimmune disease (n =4; 5%), exclusion of
significant bacterial growth to start steroids (n =2; 2%)
and undefined (n =3; 4%). The main characteristics of
the patients are listed in Table 1. Among the 82 enrolled
patients, 23 were female (28%), mean patient age was
59 ±17 years, mean Simplified Acute Physiology Score
II at the time of ICU admission was 46 ±15 and in-
hospital mortality was 30% (n =25).
Identification of bronchoalveolar lavage fluid PTX3
threshold for microbiologically confirmed pneumonia
diagnosis
Among patients enrolled in the study, data review by two
independent physicians blinded to biomarker levels and
the initial diagnosis yielded coincident results in 79 cases
(agreement rate =0.963, Cohen’s κ =0.911). The three con-
troversial cases were then jointly reviewed, and consensus
was achieved in all of them. Lung infection was diagnosed
in 24 cases (29%); among these, 14 were VAP (58%), 7
were HAP (30%) and 3 were CAP (12%). No HCAP case
was identified. The etiology of pneumonia was bacterial in
12 cases (50%), fungal in 8 (33%) and viral in 4 (25%) (see
Table E1 in Additional file 1). When BAL was performed,
clinical criteria for the diagnosis of pneumonia were lack-
ing in 12 cases (15%).
PTX3 levels in BAL fluid was the only mediator signifi-
cantly higher in the presence of pneumonia compared to
noninfection cases (P <0.0001) (Table 1). AUC
ROC analysis
showed that PTX3 levels in BAL fluid predicted pneumo-
nia (AUC
ROC =0.815, 95% CI =0.710 to 0.921, P <0.0001),
whereas BAL fluid levels of sTREM-1, plasma PTX3,
sTREM-1, CRP and PCT did not (Figure 2). A cutoff level
of PTX3≥1 ng/ml in BAL fluid (identified by Youden
Figure 1 Flow diagram for the study cohort. BAL, Bronchoalveolar lavage; ICU, Intensive care unit; MGH, Massachusetts General Hospital; PTX,
Pentraxin 3; SICU, Surgical intensive care unit.
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cificity, 49% PPV and 95% NPV for culture-positive
pneumonia. Total accuracy was 70%. Of the two pa-
tients with pneumonia and PTX3 level <1 ng/ml in BAL
fluid, one had bacterial CAP and the other had fungal
HAP and immunosuppression (which could have
determined low PTX3 levels). Among the 23 patients
without pneumonia and with PTX3 levels ≥1n g / m li n
BAL fluid, 5 had cardiogenic pulmonary edema, 9 had
ARDS of extrapulmonary origin, 4 had primary nonin-
fectious ARDS and 2 had acute exacerbations of chronic
obstructive pulmonary disease (all representing acute
Table 1 Main characteristics at the time of bronchoalveolar lavage fluid and plasma sampling in the study cohort
a
Characteristics All BAL
(N = 82)
Pneumonia
(n = 24, 29%)
No pneumonia
(n = 58, 71%)
Days since hospital admission 8 (4 to 16) 5.5 (2.5 to 10.5) 9 (6 to 17)
Comorbidities, n (%)
Hypertension 21 (26) 6 (25) 15 (26)
Ischemic vascular disease 14 (17) 5 (21) 9 (16)
Diabetes 9 (11) 2 (8) 7 (12)
COPD 12 (15) 4 (17) 8 (14)
Malignancy 16 (20) 6 (25) 10 (17)
Chronic kidney disease 6 (7) 2 (8) 4 (7)
Other 10 (12) 3 (12) 7 (12)
Days since intubation 2 (1 to 7) 2 (0.5 to 6.5) 2.5 (1 to 7)
FiO2, % 50 (40 to 70) 57.5 (40 to 62.5) 50 (40 to 70)
PaO2/FiO2 ratio, mmHg 188.6 (138.0 to 232.0) 198.4 (144.3 to 249.9) 178.2 (136.7 to 220)
PEEP, cmH2O 10 (8 to 12) 10 (8 to 12) 10 (8 to 12)
Vt, ml/kg 6.6 ± 2.2 7.4 ± 1.9 6.3 ± 2.2
Body temperature, °C 37.9 (36.9 to 38.5) 37.6 (36.7 to 38.4) 38.0 (37.0 to 38.50)
White blood cells, 10
3/mm
3 11.5 (8.7 to 15.9) 13.4 (7.7 to 17.3) 11.3 (8.9 to 14.9)
Heart rate, beats/min 90.6 ± 18.2 96.6 ± 15.6 88.1 ± 18.8
SOFA score 6 (4 to 8) 7 (4.5 to 10) 6 (4 to 8)
Organ failures, n 2 (1 to 2) 2 (1 to 3) 2 (1 to 2)
Septic shock, n (%) 28 (34) 9 (38) 19 (33)
Immunosuppression, n (%) 20 (24) 8 (33) 12 (21)
Receiving antibiotics, n (%) 73 (89) 21 (88) 52 (90)
CPIS 3 (2 to 5) 4 (2.5 to 5) 3 (2 to 5)
Plasma PCT, ng/ml 1.0 (0.3 to 6.1) 2.1 (0.4 to 8.2) 0.9 (0.3 to 4.0)
Plasma CRP, mg/dl 13.9 (7.5 to 22.7) 9.5 (6.0 to 21.7) 14.4 (7.7 to 23.6)
Plasma sTREM-1, pg/ml 346.0 (216.0 to 685.0) 345.0 (230.5 to 779.5) 352.0 (216.0 to 620.0)
Plasma PTX3, ng/ml 56.2 (31.4 to 127.4) 62.7 (31.0 to 174.1) 54.3 (31.4 to 110.5)
BAL fluid sTREM-1, pg/ml 0 (0 to 281) 42.5 (0 to 316) 0 (0 to 247)
BAL fluid PTX3, ng/ml 1.2 (0.3 to 7.4) 8.3 (1.6 to 29.5)
b 0.6 (0.0 to 3.4)
Semiquantitative BAL fluid leukocyte count, n (%)
− 10 (12) 1 (4) 9 (15)
+ 25 (30) 4 (17) 21 (36)
++ 24 (30) 11 (46) 13 (22)
+++ 23 (28) 8 (33) 15 (26)
a−, No leukocytes; +, Few leukocytes; ++ and +++, Many leukocytes; BAL, Bronchoalveolar lavage; COPD, Chronic obstructive pulmonary disease; CPIS, Clinical
Pulmonary Infection Score; CRP, C-reactive protein; FiO2, Fraction of inspired oxygen; PaO2, Partial pressure of oxygen in arterial blood; PCT, Procalcitonin; PEEP,
Positive end-expiratory pressure; PTX3, Pentraxin 3; SOFA, Sequential Organ Failure Assessment; sTREM-1, Soluble triggering receptor expressed on myeloid cells 1;
Vt, Tidal volume. Mean ± standard deviation values are indicated for normally distributed variables, and median (interquartile range) values are given for
non-normal variables.
bP < 0.0001 vs. no pneumonia.
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cific biomarkers like PTX3), and a final diagnosis could
not be determined in 3 patients.
Net reclassification indexes for PTX3 levels ≥1n g / m li n
BAL fluid were elevated (range =0.38 to 0.55) in compari-
son to all other mediators and to CPIS with gain in sensi-
tivity, specificity or both (Table 2). In univariate prediction
analysis, PTX3 levels ≥1 ng/ml in BAL fluid significantly
predicted pneumonia (β =2.784, SE =0.792, P <0.001); all
other biomarkers were not effective (Table 3).
Bronchoalveolar lavage fluid PTX3 levels in patients with
confirmed bacterial pneumonia
When we compared the 58 negative cases to the 12 pa-
tients with proven bacterial pneumonia (total N =70),
PTX3 diagnostic accuracy was confirmed by AUC-ROC
analysis (AUC
ROC =0.827, 95% CI =0.668 to 0.987, P
<0.0001); however, BAL fluid sTREM-1, plasma PTX3,
sTREM-1, CRP and PCT levels were not predictive of bac-
terial pneumonia (see Figure E1 in Additional file 1). A
new cutoff level of PTX3 levels ≥7 ng/ml in BAL fluid
(identified by Youden index [32]) was associated with 75%
sensitivity, 88% specificity, 56% PPV and 94% NPV for
confirmed bacterial pneumonia. Total accuracy was 70%.
Net reclassification indexes for PTX3 levels ≥7n g / m li n
BAL fluid were elevated (range =0.32 to 0.66) in compari-
son to all other mediators and to CPIS with gains in sensi-
tivity, specificity or both. In univariate prediction analysis,
PTX3 levels ≥7 ng/ml in BAL fluid significantly predicted
pneumonia (β =2.931, SE =0.768, P <0.001), whereas all
other mediators could not predict bacterial pneumonia.
Bronchoalveolar lavage fluid PTX3 levels in patients who
fulfilled clinical criteria for pneumonia
When we considered only the 70 patients who fulfilled
clinical criteria for the diagnosis of pneumonia at the
time of BAL fluid sampling, PTX3 diagnostic accuracy
was confirmed both by both the AUC
ROC curve
(AUC
ROC =0.838, 95% CI =0.737 to 0.941, P <0.0001)
and univariate analysis (PTX3 levels ≥1 ng/ml in BAL
fluid: β =3.065, SE =0.809, P <0.001), whereas all other
mediators could not predict pneumonia.
Results of immunostaining to measure cell fractions
positive for intracellular PTX3
Cells retrieved by BAL with intracellular PTX3 were
present in all immunostained samples (n =20, all from
Figure 2 Pentraxin 3 as an early marker of pneumonia. Area
under the receiver operating characteristic curve (AUC
ROC) analysis
showed that Pentraxin 3 (PTX3) levels in bronchoalveolar lavage fluid
(BALf) levels predicted pneumonia (AUC
ROC =0.815, 95% CI =0.710 to
0.921, P <0.0001), but that BALf levels of soluble triggering receptor
expressed on myeloid cells 1 (s-TREM-1), plasma PTX3, C-reactive
protein (CRP) and procalcitonin (PCT) levels did not. A cutoff of PTX3
levels ≥1 ng/ml in BAL fluid (identified by Youden index) was
associated with 92% sensitivity, 60% specificity, 49% positive predictive
value and 95% negative predictive value for culture-positive
pneumonia.
Table 2 Comparison of net reclassification index values
for PTX3 levels in bronchoalveolar lavage fluid
a
Comparisons with BAL fluid PTX3 ≥1 ng/ml ΔSe Δ(1-SP) NRI
Plasma PTX3 ≥130 ng/ml 0.58 −0.21 0.38
Plasma PCT ≥0.5 ng/ml 0.25 0.19 0.44
Plasma CRP ≥0.5 mg/dl −0.09 0.61 0.52
BAL fluid sTREM-1 ≥5 pg/ml 0.38 0.07 0.44
Plasma sTREM-1 ≥5 pg/ml −0.04 0.60 0.56
CPIS ≥7 0.88 −0.34 0.53
aBAL, Bronchoalveolar lavage fluid; CPIS, Clinical Pulmonary Infection Score;
CRP, C-reactive protein; NRI, Net reclassification index; PCT, Procalcitonin; PTX3,
Pentraxin 3; ΔSe, Change in sensitivity; Δ(1-SP), Change in 1-specificity;
sTREM-1, Soluble triggering receptor expressed on myeloid cells 1.
Table 3 Univariate analysis for prediction of
microbiologically confirmed pneumonia
a
Variables Univariate β SE P-value
BAL fluid PTX3 ≥1 ng/ml 2.784 0.792 <0.001
Plasma PTX3 ≥130 ng/ml 0.742 0.576 0.198
Plasma PCT ≥0.5 ng/ml 0.506 0.532 0.342
Plasma CRP ≥0.5 mg/dl
b –– –
BAL fluid sTREM-1 ≥5 pg/ml 0.438 0.507 0.389
Plasma sTREM-1 ≥5 pg/ml
c –– –
CPIS ≥7 −0.192 1.183 0.871
aBAL, Bronchoalveolar lavage fluid; CPIS, Clinical Pulmonary Infection Score;
CRP, C-reactive protein; PCT, Procalcitonin; PTX3, Pentraxin 3; SE, standard
error; sTREM-1, Soluble triggering receptor expressed on myeloid cells 1.
bCould not be determined because all values were >0.5 mg/dl.
cCould not be
determined, as estimates were not reliable because of convergence problems
of the statistical model.
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in BAL fluid positive for intracellular PTX3 was 36%
(IQR =32% to 51%) (Figure 3). PTX3 levels in BAL fluid
levels and percentages of cells in BAL fluid positive for
intracellular PTX3 were not correlated (P >0.05; data not
shown). More results can be found in Additional file 1.
Discussion
Main findings
In a convenience sample of intubated critically ill patients
undergoing BAL as per clinical decision, alveolar PTX3
was an early marker of microbiologically confirmed pneu-
monia with better diagnostic accuracy than other bio-
markers. The diagnostic accuracy of PTX3 was confirmed
when we limited our analyses only to proven bacterial
pneumonia cases or to patients who fulfilled clinical cri-
teria for pneumonia at the time of BAL fluid sampling.
Bronchoalveolar lavage fluid PTX3 levels and diagnosis
of pneumonia
Pneumonia represents one of the most widespread infec-
tions in intubated ICU patients [6] and is associated with
significant morbidity (for example, prolonged mechan-
ical ventilation, end-stage organ failure), costs and mor-
tality [6]. Timely and accurate diagnosis of pneumonia is
crucial to starting appropriate treatment and improving
patients’ recovery and survival. However, to date, a rapid
and accurate approach to diagnose pneumonia in intu-
bated critically ill patients is lacking [2]. The aim of the
present study was to describe the use of PTX3 levels in
BAL fluid as a potentially new marker for early and ac-
curate diagnosis of pneumonia. The study design was
observational in one population of unselected intubated
critically ill patients. Our results indicate that rapid assay
of PTX3 levels in BAL fluid can predict the presence of
lung infection about 48 hours before culture data be-
come available [4]. To help with translation to the clin-
ical setting, we identified a cutoff level of 1 ng/ml as
being associated with the highest sum of sensitivity and
specificity [32], and we found that this level was associ-
ated with high diagnostic accuracy. In particular, PTX3
levels ≥1 ng/ml in BAL fluid showed high sensitivity and
NPV. This indicates that PTX3 levels ≥1 ng/ml in BAL
fluid only rarely misclassify a patient with pneumonia as
being uninfected. This is probably the most clinically
relevant result we can report, as recognition of true
negative cases is crucial for antibiotics stewardship
aimed at reducing microbial resistance [6]. The same re-
sults were confirmed when we performed a post hoc
analysis of proven bacterial pneumonia cases, with a
higher threshold (7 ng/ml) and, possibly, improved spe-
cificity. Moreover, when we restricted our analysis to the
subgroup of patients who met clinical criteria for pneu-
monia at the time of BAL, our results were also con-
firmed. In this subset of patients, pretest probability was
higher and the diagnostic accuracy of a screening test
such as PTX3 was expected to be poorer. Another
strength of the study is that oxygenation did not differ
between infected and uninfected patients. We previously
showed that plasma PTX3 level is correlated with
the severity of ARDS [28], but this did not seem to
bias the present results. Our data thus lead us to the
working hypothesis that PTX3 level in BAL fluid is
discriminative of confirmed pneumonia in intubated
ICU patients. In the future, adequately powered pro-
spective trials may validate PTX3 level measured in
BAL fluid assays as a marker of pneumonia and test
whether it has any clinical value in guiding prescrip-
tion of antibiotics.
Comparative diagnostic accuracy
In our study, alveolar PTX3 was an independent marker of
pneumonia due to any etiology with elevated NRI values in
comparison to other mediators and to CPIS. In 2004, in an
observational single-center study, Gibot and colleagues pro-
posed sTREM-1 as an early and accurate marker of pneu-
monia [8]. However, none of the patients enrolled in their
study presented with viral pneumonia [8]. In two more re-
cent studies, researchers found that sTREM-1 levels in BAL
fluid are not discriminativef o rp n e u m o n i ai ni n t u b a t e d
ICU patients [12,13]. Large validation studies on the role of
Figure 3 Pentraxin 3 is stored in alveolar cell granules.
Immunostained images show intracellular presence of Pentraxin 3
(PTX3) inside one cell (red arrow) recovered from the alveolar space of
an intubated critically ill patient. In the present study, cells recovered
from 20 consecutive bronchoalveolar lavage (BAL) procedures in 20
intubated critically ill patients (see the immunostaining paragraph in
the Methods section for details) were stained to measure the fraction
of cells remaining after BAL that were positive for intracellular PTX3.
The shape of the cell in this picture resembles that of an alveolar
leukocyte, which constitutively stores PTX3 inside specific granules.
Green represents a fluorescent anti-human PTX3 antibody, and blue
are is the cell nucleus stained with bisbenzimide. Yellow arrows
indicate nuclei of BAL cells that, apparently, don't store PTX3.
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encouraging results [10]. Our results on the association
between circulating PCT and pneumonia diagnosis, at
variance, are poor. There are various possible reasons
for this apparent contrast. First, in the PCT arm of the
PRORATA trial, antibiotics were prescribed and
stopped based on variations in PCT levels, thus imply-
ing an association between the trend of PCT levels in
time and infection [10]. Second, a lack of association be-
t w e e nt h eP C Tv a l u ei no n es a m p l ea n dp n e u m o n i a
diagnosis has also been shown by other recent studies
[33]. Third, PCT is known to have no diagnostic value
in pneumonia of nonbacterial origin [10]. CPIS is a clin-
ical test for screening VAP cases in intubated critically
i l lp a t i e n t s[ 9 ] .H o w e v e r ,i no u rp o p u l a t i o n ,C P I Sy i e l d e d
poor results in predicting pneumonia. To this end, one
should consider that CPIS has been validated only in
VAP and that 56% of our sample were non-VAP cases.
A possibly higher diagnostic accuracy of PTX3 levels in
BAL fluid in comparison to other biomarkers was con-
firmed in the post hoc analysis of proven bacterial pneu-
monia cases.
Thus, our study indicates that, in intubated critically
ill patients, the accuracy of PTX3 levels in BAL fluid for
diagnosing pneumonia might be superior to other
current biomarkers and clinical markers, especially
when nonbacterial and/or non-VAP cases are suspected.
Still, the diagnostic value of plasma PTX3 might be
markedly increased by serial measurements over time
(for example, at 24 to 48 hours after BAL) [22], which
could be tested in future studies.
Correlation between intra- and extracellular alveolar PTX3
Previous studies showed that neutrophils, which constitu-
t i v e l ys t o r eP T X 3i ns p e c i f i cg r a n u l e s ,r a p i d l yr e l e a s eP T X 3
in response to microorganisms and many other inflamma-
tory stimuli [18-20,28]. In our population, we found a high
prevalence of cells in BAL fluid that stained positive for
intracellular PTX3 by anti-hPTX3 rabbit antibodies [30],
which may be the result of new recruitment of fresh leuko-
cytes in response to the infection. In our patients, PTX3
levels in BAL fluid were not correlated with the percentage
of intracellular PTX3-positive cells. Besides the relevance of
leukocyte activation in the lungs of mechanically ventilated
ICU patients who may be infected [34], other factors may
play a role in determining PTX3 levels in BAL fluid. Rapid
induction of PTX3 expression has been described in a var-
iety of different cell types and as being involved in host local
response during lung infections: monocytes, macrophages,
alveolar epithelial and endothelial cells, and fibroblasts [21].
Thus, the lack of association between intra- and extracellu-
lar alveolar PTX3 may be due to the combination of de novo
synthesis of the protein by immune and stromal cells and
release of the stored protein from leukocytes.
Study limitations
This study has many limitations, and therefore the informa-
tion regarding alveolar PTX3 should be interpreted with
caution. (1) We conducted an observational, hypothesis-
generating study with a relatively modest sample size, and
the clinical impact of PTX3 levels in BAL fluid-based pro-
tocols for the diagnosis of pneumonia and for prescribing
(or withholding) of antibiotics remains to be determined in
larger, prospective randomized studies. (2) The timing of
BAL was not preplanned; instead, we collected BAL fluid
whenever the attending physician decided to perform BAL,
to the point that 15% of total cases did not fulfill the clinical
criteria for pneumonia. In this way, we could evaluate
PTX3 diagnostic performance in real-life clinical routine.
Moreover, all results were confirmed in the subgroup of
cases with clinical criteria for suspected pneumonia. (3)
The PTX3 assay used in this stu d yh a sar e l a t i v e l yn a r r o w
dynamic range, thus requiring dilution of biological samples
with higher concentrations. This may limit the clinical ro-
bustness of the results, as translation into routine practice
is far easier with tests involving undiluted samples. How-
ever, 60% of the BAL fluid samples, which were the main
focus of this study, were tested without any dilution, as they
were within the assay dynamic range. Nonetheless, more ef-
fort should be put into development of new PTX3 assays
with wider dynamic ranges to help bench-to-bedside trans-
lation. (4) Immunostaining was performed in only 20 BAL
fluid samples (24%); however, the immunostained samples
were consecutive and pneumonia incidence and PTX3
levels in BAL fluid in this subgroup closely resembled those
of the whole study population. (5) Pneumonia cases of dif-
ferent etiologies were included in the study, which intro-
duced some heterogeneity. Cytomegalovirus, Candida spp
and A. fumigatus pneumonia are difficult to diagnose unless
invasive methods not reported in the present study are
used. Moreover, the comparison with biomarkers not ex-
pected to increase in the presence of viral or fungal infec-
tions is a major limitation. Therefore, to increase practical
implications, we performed a post hoc analysis limited to
proven bacterial infections that confirmed the diagnostic
accuracy of PTX3 levels in BAL fluid. (6) In a recent study,
researchers showed that receipt of hematopoietic stem cell
transplantation from a donor with a homozygous defective
expression of PTX3 in neutrophils was associated with an
increased risk of invasive aspergillosis [35]. Thus, alveolar
PTX3 levels <1 ng/ml warrant caution in their interpret-
ation in patients who raise high clinical suspicion for inva-
sive aspergillosis.
Conclusions
Our study shows that, in a convenience sample of unse-
lected intubated critically ill patients undergoing BAL,
alveolar PTX3 level is discriminative for microbiologic-
ally confirmed lung infection. In particular, PTX3 levels
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tivity and NPV, which may enable timely and accurate rec-
ognition of the vast majority of true negative cases. Future
studies designed to validate the PTX3 threshold and fur-
ther investigate the role of PTX3 levels in BAL fluid to
guide antimicrobial therapy seem warranted.
Key messages
 Early diagnosis of pneumonia in intubated ICU
patients is fundamental but rather challenging, as
clinical criteria yield many false-positive results.
 Pentraxin 3 is an acute-phase inflammatory medi-
ator involved in the local recognition and clearance
of bacteria, viruses and fungi.
 In the present study, Pentraxin 3 proved to be a
useful early marker of pneumonia, with high
negative predictive value, in intubated ICU patients.
 A discriminative threshold PTX3 level ≥1 ng/ml in
BAL fluid was identified to help translation into
clinical practice, but validation is still required.
Additional file
Additional file 1: Additional details regarding methods and results
are provided. The file also contains additional references, one table on
BAL fluid microbiology results and one figure illustrating the diagnostic
accuracy of PTX3 as a marker of confirmed bacterial pneumonia.
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